Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial
Martin Kaiser(Royal Marsden NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Gordon Cook(University of Leeds), Christina Messiou(Institute of Cancer Research), Mark T. Drayson(Institute of Immunology), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Nicola Newnham(University of Birmingham), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Ruth M. de Tute(St James's University Hospital), Sarah Brown(University of Leeds), Katrina Walker(University of Leeds), Emma Ingleson(University of Leeds), Sadie Roberts(University of Leeds), Andrew Hall(University of Leeds), Graham Jackson(Newcastle College), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Kristian M. Bowles(University of East Anglia)
Cited by 9
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605